Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris

This study has been terminated.
Information provided by:
Jacobus Pharmaceutical Identifier:
First received: January 29, 2007
Last updated: February 1, 2007
Last verified: February 2007
The purpose of this 12-month study was to determine the efficacy of dapsone as a glucocorticoid-sparing agent in maintenance phase pemphigus vulgaris.

Condition Intervention Phase
Pemphigus Vulgaris
Drug: Dapsone
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Prospective Randomized Placebo-Controlled Clinical Trial of Dapsone as a Glucocorticoid-Sparing Agent in Maintenance Phase Pemphigus Vulgaris

Resource links provided by NLM:

Further study details as provided by Jacobus Pharmaceutical:

Primary Outcome Measures:
  • The ability of patients to taper to ≤7.5mg/day within one year of reaching the maximum dosage of the study drug.

Secondary Outcome Measures:
  • Steroid dosage reduced by more than 25% within 4 months after completing the upward titration of the study drug.

Estimated Enrollment: 48
Study Start Date: November 1996
Estimated Study Completion Date: February 2004
Detailed Description:
Patients were entered into the trial on steroids in combination with cytotoxic agents as needed. The steroid dose was the lowest dose at which the patient’s disease was controlled before the last flare (see eligibility criteria). The patients were randomized to receive either Dapsone or placebo. Treatment was to be started at a dose of 50 mg and increased by 25 mg increments each week once the hemoglobin was shown not to have dropped by more than 2 gm/dl. The target dose was 150 mg and patients who did not respond could be advanced to 200 mg daily. After beginning treatment, a standardized steroid taper was commenced. A standardized steroid taper was suggested with tapering by 10 mg/wk for doses above 40 mg/day or more slowly if warranted. A slower taper thereafter or an every other day dosing schedule would be elected according to the individual investigator’s preference. Flares were treated by increasing the dose of steroids - in the case of a mild flare to the last dose preceding the flare, in the case of a moderate flare by 20 mg/day and in the case of a severe flare by 40 mg/day. Tapering was to be resumed once the disease had stabilized. Disease activity was assessed by a simple scoring system for skin, mucosa, and sites involved. Laboratory assessments initially weekly became monthly once the study medication dosage was stabilized.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologic evidence compatible with pemphigus vulgaris and direct immunofluorescence evidence of pemphigus vulgaris.
  • Chronic disease that has been controlled with steroids and/or cytotoxics, e.g. maintenance phase.
  • On prednisone 15 or more mg/day to around 40 mg/day or on prednisone 15 or more mg every other day (qod) to around 40 mg qod.
  • Failure to taper steroids below a range of 15 mg/day to around 40 mg/day or 15 mg/qod to around 40 qod without flaring the disease.
  • The steroid dosage at which the most recent flare occurred should not be less than 85% of the last (within 30 days) dosage which controlled the disease, i.e. 85% of the baseline steroid dosage. This is to ensure that patients will not have had a recent acute flare at the time of entry into the study, and be in the rapid steroid taper portion of their disease after such a flare.
  • Two baseline steroid dosages as determined by prior flares. It is common that patients will be repetitively unable to taper below a certain baseline steroid dose without experiencing a mild flare of their disease. This baseline dose will be determined on two occasions during attempted tapers, and the baseline number then averaged to determine the dose of steroid the patient is on at the time of entry into the study.
  • No pulse steroids, pulse cyclosphosphamide, or plasmapheresis within two months of beginning the protocol. This will exclude patients who had recent acute flares of their disease and may be on the rapid steroid taper portion of their disease. The patient must be in maintenance phase, as defined in the criteria listed in e.
  • Patient understands the procedures and agrees to participate in the study program by giving written informed consent.

Exclusion Criteria:

  • Patients able to taper steroids without recurrence of disease.
  • Patients with early, severe disease that have not responded to high doses of prednisone, cytotoxics, plasmapheresis, or other modalities.
  • Contraindications to the use of Dapsone, including severe anemia or G6PD deficiency.
  • Patient has behavioral problems that might interfere with compliance.
  • Pregnancy or breast-feeding.
  • Younger than 18 or older than 80 years of age. Since PV is rare in patients younger than 18, it was decided to exclude this potentially different population. It is unlikely that this will exclude many patients. Dapsone induces a hemolytic anemia, which would be a particular problem for patients over age 80, who are more likely to have ischemic heart disease or other atherosclerotic vascular disease.
  • History of allergy to dapsone.
  • Ischemic heart disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00429533

United States, Illinois
Northwestern University Medical Center
Chicago, Illinois, United States, 60611-3010
Rush-Presbyterian-St. Luke's Medical Center
Chicago, Illinois, United States, 60612
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
United States, New Jersey
Cooper Hospital/University Medical Center
Camden, New Jersey, United States, 08103
United States, New York
The New York VA Medical Center, New York University
New York, New York, United States, 10010
United States, Ohio
Case Western Reserve University School of Medicine
Cleveland, Ohio, United States, 44106
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
University of Texas
Dallas, Texas, United States, 75235
Sponsors and Collaborators
Jacobus Pharmaceutical
Study Chair: Victoria P. Werth, MD University of Pennsylvania
Principal Investigator: Victoria P. Werth, MD University of Pennsylvania
Principal Investigator: Diana Chen, MD Northwestern University
Principal Investigator: Warren R Heymann, MD Cooper Hospital/University Medical Center
Principal Investigator: Neil Korman, MD Case Western Reserve University School of Medicine
Principal Investigator: Amit Pandya, MD University of Texas
Principal Investigator: M J Rico, MD The New York VA Medical Center - New York University
Principal Investigator: Michael D Tharp, MD Rush University Medical Center
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00429533     History of Changes
Other Study ID Numbers: 51,988
Study First Received: January 29, 2007
Last Updated: February 1, 2007

Additional relevant MeSH terms:
Skin Diseases, Vesiculobullous
Skin Diseases
Autoimmune Diseases
Immune System Diseases
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Leprostatic Agents
Anti-Bacterial Agents processed this record on April 24, 2017